608 related articles for article (PubMed ID: 27659671)
21. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
Horie R; Handa O; Ando T; Ose T; Murakami T; Suzuki N; Sendo R; Imamoto E; Itoh Y
Helicobacter; 2020 Aug; 25(4):e12698. PubMed ID: 32368846
[TBL] [Abstract][Full Text] [Related]
22. Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis.
Deguchi H; Yamazaki H; Kamitani T; Yamamoto Y; Fukuhara S
Adv Ther; 2021 Jul; 38(7):3937-3947. PubMed ID: 34091865
[TBL] [Abstract][Full Text] [Related]
23. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
Bunchorntavakul C; Buranathawornsom A
J Gastroenterol Hepatol; 2021 Dec; 36(12):3308-3313. PubMed ID: 34622504
[TBL] [Abstract][Full Text] [Related]
24. Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen.
Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kobayashi Y; Miura Y; Lefor AK; Yamamoto H
Kaohsiung J Med Sci; 2018 Aug; 34(8):456-460. PubMed ID: 30041763
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Suzuki S; Gotoda T; Kusano C; Iwatsuka K; Moriyama M
Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
[TBL] [Abstract][Full Text] [Related]
26. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
[TBL] [Abstract][Full Text] [Related]
27. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
28. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
[No Abstract] [Full Text] [Related]
29. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.
Gunaratne AW; Hamblin H; Clancy A; Magat AJMC; Dawson MVM; Tu J; Borody TJ
Helicobacter; 2021 Oct; 26(5):e12830. PubMed ID: 34247436
[TBL] [Abstract][Full Text] [Related]
30. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
[TBL] [Abstract][Full Text] [Related]
31. Comparative study: Vonoprazan and proton pump inhibitors in
Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
[TBL] [Abstract][Full Text] [Related]
32. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
[TBL] [Abstract][Full Text] [Related]
33. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
[TBL] [Abstract][Full Text] [Related]
34. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
35. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
Ratana-Amornpin S; Sanglutong L; Eiamsitrakoon T; Siramolpiwat S; Graham DY; Mahachai V
Helicobacter; 2023 Dec; 28(6):e13019. PubMed ID: 37723133
[TBL] [Abstract][Full Text] [Related]
36. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
Tsujimae M; Yamashita H; Hashimura H; Kano C; Shimoyama K; Kanamori A; Matsumoto K; Koizumi A; Momose K; Eguchi T; Fukuchi T; Fujita M; Okada A
Digestion; 2016; 94(4):240-246. PubMed ID: 28030862
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
[TBL] [Abstract][Full Text] [Related]
38. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.
Lee HJ; Kim JI; Cheung DY; Kim TH; Jun EJ; Oh JH; Chung WC; Kim BW; Kim SS; Park SH; Kim JK
J Infect Dis; 2013 Oct; 208(7):1123-30. PubMed ID: 23801607
[TBL] [Abstract][Full Text] [Related]
39. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
Sue S; Maeda S
Gut Liver; 2021 Nov; 15(6):799-810. PubMed ID: 33850058
[TBL] [Abstract][Full Text] [Related]
40. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
Liu L; Shi H; Shi Y; Wang A; Guo N; Li F; Nahata MC
Helicobacter; 2024; 29(3):e13094. PubMed ID: 38790090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
